Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials

Vaccine

Volumn 23, Issue 17-18, 2005, Pages 2218-2221

  Martin, D ^a   McCallum, L ^a   Glennie, A ^a   Ruijne, N ^a   Blatchford, P ^a   O'Hallahan, J ^b   Oster, P ^c  

^a INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^b MINISTRY OF HEALTH   (New Zealand)

^c CHIRON VACCINES   (Italy)

Author keywords

Immune response; Serum bactericidal assay; Validation

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ANTIBODY DETECTION; ANTIBODY TITER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SEROCONVERSION; SERUM BACTERICIDAL ACTIVITY; VALIDATION PROCESS;

EID: 14844300796     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.070     Document Type: Conference Paper

References (10)

1. G.V.G. Sierra, H.C. Campa, N.M. Varcacel, I.L. Garcia, P.L. Izquierdo, and P.F. Sotolongo Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba NIPH Ann 14 1991 195 207
2. E.A. Hoiby, E. Rosenqvist, L.O. Froholm, G. Bjune, B. Feiring, and H. Nokleby Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey NIPH Ann 14 1991 147 154
3. Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, et al. The New Zealand meningococcal vaccine strategy: a tailor made vaccine to combat a devastating epidemic. NZMJ 2004117. http://www.nzma.org.nz/journal/117-1200/ 1015.
4. C.E. Frasch, and J.D. Robbins Protection against meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model J Exp Med 147 1978 629 644
5. L.G. Milagres, S.R. Ramos, C.T. Sacchi, C.E.A. Melles, V.S.D. Vieira, and H. Sato Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy Infect Immun 62 1994 4419 4424
6. B.A. Perkins, K. Jonsdottir, H. Briem, E. Griffiths, B.D. Plikaytis, and E.A. Hoiby Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland J Infect Dis 177 1998 683 691
7. A.J. Pollard, R. Galassisi, E.M. Rouppe van der Voort, R. Booy, P. Langford, and S. Nadel Humoral immune responses to Neisseria meningitidis in children Infect Immun 67 1999 2441 2451
8. E. Rosenqvist, E.A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, and A. Klem Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine Infect Immun 63 1995 4642 4652
9. J. Boslego, J. Garcia, C. Cruz, W. Zollinger, B. Brandt, and S. Ruiz Efficacy, safety, and immunogenicity of a meningococcal group B (15,P1.3) outer membrane protein vaccine in Iquique, Chile Vaccine 13 1995 821 829
10. J.W. Tappero, R. Lagos, A.M. Ballesteros, B. Plikaytis, D. Williams, and J. Dykes Immunogenicity of 2 serogroup B outer-membrane protein vaccines. A randomised controlled trial in Chile JAMA 281 1999 1520 1527